1 of 1
Story summary
- The FDA issued a warning letter to Empower Pharmacy for mass-copying GLP-1 weight-loss drugs.
- The warning letter, dated Sept. 18, was posted online Sept. 24, 2026.
- An FDA inspection in Nov. 2025 found Empower’s orders lacked prescriber justification and undisclosed volumes.
- Eli Lilly sued Empower, alleging deceptive marketing of sham “personalized” knockoff products.
- Novo Nordisk publicly objected and joined legal actions against Empower’s compounded GLP-1 drugs.
